Austedo® is the commercial brand name of Deutetrabenazine Tablets, an oral deuterated VMAT‑2 inhibitor developed by Teva Pharmaceuticals. It reversibly inhibits vesicular monoamine transporter 2, reducing presynaptic dopamine release to alleviate involuntary hyperkinetic movement disorders.
Main Indications
Treatment of chorea associated with Huntington’s disease in adult patients;
Treatment of tardive dyskinesia in adult patients.
Clinical Research
Global multicenter phase‑III placebo‑controlled trials demonstrated that deutetrabenazine significantly reduces involuntary choreatic movements in Huntington’s disease patients and improves symptoms of tardive dyskinesia;
Compared with tetrabenazine, deuterium‑modified deutetrabenazine shows more stable pharmacokinetic properties and lower frequency of dose‑limiting adverse events;
Chinese clinical trials confirmed its clinical efficacy and safety profile are consistent with global study outcomes for local patient populations.
Common Side Effects
Serious risks: depression, suicidal ideation and behaviors, parkinsonism, bradykinesia, akathisia;
Common mild adverse reactions: somnolence, fatigue, diarrhea, insomnia, anxiety, dizziness.
Approval Status in China
Original drug Austedo® (Deutetrabenazine Tablets) obtained marketing authorization in China in 2020, with specifications including 6 mg. It is currently a prescription drug covered by Chinese medical insurance.
Buy Austedo (Deutetrabenazine Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
